Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 352

The DOI matches its Crossref record.

The energy-less red blood cell is lost: erythrocyte enzyme abnormalities of glycolysis

Open access
van Wijk, Richard, van Solinge, Wouter W.·2005·Blood
DOI 10.1182/blood-2005-04-1622
Open this paper in CoChat — free account

Abstract

The red blood cell depends solely on the anaerobic conversion of glucose by the Embden-Meyerhof pathway for the generation and storage of high-energy phosphates, which is necessary for the maintenance of a number of vital functions. Many red blood cell enzymopathies have been described that disturb the erythrocyte's integrity, shorten its cellular survival, and result in hemolytic anemia. By far the majority of these enzymopathies are hereditary in nature. In this review, we summarize the current knowledge regarding the genetic, biochemical, and structural features of clinically relevant red blood cell enzymopathies involved in the Embden-Meyerhof pathway and the Rapoport-Luebering shunt.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2005-04-1622

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 113

  1. Surgenor DM. The Red Blood Cell. New York, NY: Academic Press; 1974.
  2. Benesch R, Benesch RE. The effect of organic phosphates from the human erythrocyte on the allosteric properties of hemoglobin. Biochem Biophys Res Commun. 1967;26: 162-167. · DOI · Paper page
  3. Miwa S. Hereditary disorders of red cell enzymes in the Embden-Meyerhof pathway. Am J Hematol. 1983;14: 381-391. · DOI
  4. Valentine WN, Tanaka KR, Paglia DE. Hemolytic anemias and erythrocyte enzymopathies. Ann Intern Med. 1985;103: 245-257. · DOI
  5. Beutler E. The molecular biology of G6PD variants and other red cell enzyme defects. Annu Rev Med. 1992;43: 47-59. · DOI
  6. Arya R, Layton DM, Bellingham AJ. Hereditary red cell enzymopathies. Blood Rev. 1995;9: 165-175. · DOI
  7. Valentine WN, Paglia DE. The primary cause of hemolysis in enzymopathies of anaerobic glycolysis: a viewpoint. Blood Cells. 1980;6: 819-829.
  8. Martinov MV, Plotnikov AG, Vitvitsky VM, Ataullakhanov FI. Deficiencies of glycolytic enzymes as a possible cause of hemolytic anemia. Biochim Biophys Acta. 2000;1474: 75-87. · DOI
  9. Beutler E. The relationship of red cell enzymes to red cell life-span. Blood Cells. 1988;14: 69-91.
  10. Beutler E. Selectivity of proteases as a basis for tissue distribution of enzymes in hereditary deficiencies. Proc Natl Acad Sci U S A. 1983;80: 3767-3768. · DOI
  11. Kahn A. Abnormalities of erythrocyte enzymes in dyserythropoiesis and malignancies. Clin Haematol. 1981;10: 123-138. · DOI
  12. Eber SW. Disorders of erythrocyte glycolysis and nucleotide metabolism. In: Handin RI, Lux SE, Stossel TP, eds. Blood Principles and Practice of Hematology. 2d ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2003: 1887-1914.
  13. Griffin LD, Gelb BD, Wheeler DA, Davison D, Adams V, McCabe ER. Mammalian hexokinase 1: evolutionary conservation and structure to function analysis. Genomics. 1991;11: 1014-1024. · DOI
  14. Wilson JE. Hexokinases. Rev Physiol Biochem Pharmacol. 1995;126: 65-198. · DOI · Paper page
  15. Cárdenas ML, Cornish-Bowden A, Ureta T. Evolution and regulatory role of the hexokinases. Biochim Biophys Acta. 1998;1401: 242-264. · DOI · Paper page
  16. Aleshin AE, Zeng C, Bourenkov GP, Bartunik HD, Fromm HJ, Honzatko RB. The mechanism of regulation of hexokinase: new insights from the crystal structure of recombinant human brain hexokinase complexed with glucose and glucose-6-phosphate. Structure. 1998;6: 39-50. · DOI
  17. Mulichak AM, Wilson JE, Padmanabhan K, Garavito RM. The structure of mammalian hexokinase-1. Nat Struct Biol. 1998;5: 555-560. · DOI
  18. Murakami K, Blei F, Tilton W, Seaman C, Piomelli S. An isozyme of hexokinase specific for the human red blood cell (HKR). Blood. 1990;75: 770-775. · DOI
  19. Andreoni F, Ruzzo A, Magnani M. Structure of the 5' region of the human hexokinase type I (HKI) gene and identification of an additional testis-specific HKI mRNA. Biochim Biophys Acta. 2000;1493: 19-26. · DOI
  20. Murakami K, Kanno H, Miwa S, Piomelli S. Human HKR isozyme: organization of the hexokinase I gene, the erythroid-specific promoter, and transcription initiation site. Mol Genet Metab. 1999;67: 118-130. · DOI
  21. Murakami K, Piomelli S. Identification of the cDNA for human red blood cell-specific hexokinase isozyme. Blood. 1997;89: 762-766. · DOI
  22. Kanno H. Hexokinase: gene structure and mutations. Baillieres Best Pract Res Clin Haematol. 2000;13: 83-88. · DOI
  23. Bianchi M, Magnani M. Hexokinase mutations that produce nonspherocytic hemolytic anemia. Blood Cells Mol Dis. 1995;21: 2-8. · DOI
  24. Kanno H, Murakami K, Hariyama Y, Ishikawa K, Miwa S, Fujii H. Homozygous intragenic deletion of type I hexokinase gene causes lethal hemolytic anemia of the affected fetus [letter]. Blood. 2002;100: 1930. · DOI
  25. van Wijk R, Rijksen G, Huizinga EG, Nieuwenhuis HK, van Solinge WW. HK Utrecht: missense mutation in the active site of human hexokinase associated with hexokinase deficiency and severe nonspherocytic hemolytic anemia. Blood. 2003;101: 345-347. · DOI
  26. Peters LL, Lane PW, Andersen SG, Gwynn B, Barker JE, Beutler E. Downeast anemia (dea), a new mouse model of severe nonspherocytic hemolytic anemia caused by hexokinase (HKI) deficiency. Blood Cells Mol Dis. 2001;27: 850-860. · DOI
  27. Sriram G, Martinez JA, McCabe ER, Liao JC, Dipple KM. Single-gene disorders: what role could moonlighting enzymes play? Am J Hum Genet. 2005;76: 911-924. · DOI
  28. West JD, Flockhart JH, Peters J, Ball ST. Death of mouse embryos that lack a functional gene for glucose phosphate isomerase. Genet Res. 1990;56: 223-236. · DOI
  29. Read J, Pearce J, Li X, Muirhead H, Chirgwin J, Davies C. The crystal structure of human phosphoglucose isomerase at 1.6 Å resolution: implications for catalytic mechanism, cytokine activity and haemolytic anaemia. J Mol Biol. 2001;309: 447-463. · DOI
  30. Xu W, Lee P, Beutler E. Human glucose phosphate isomerase: exon mapping and gene structure. Genomics. 1995;29: 732-739. · DOI
  31. Kugler W, Lakomek M. Glucose-6-phosphate isomerase deficiency. Baillieres Best Pract Res Clin Haematol. 2000;13: 89-101. · DOI
  32. Matthay KK, Mentzer WC. Erythrocyte enzymopathies in the newborn. Clin Haematol. 1981;10: 31-55. · DOI
  33. Schröter W, Eber SW, Bardosi A, Gahr M, Gabriel M, Sitzmann FC. Generalised glucosephosphate isomerase (GPI) deficiency causing haemolytic anaemia, neuromuscular symptoms and impairment of granulocytic function: a new syndrome due to a new stable GPI variant with diminished specific activity (GPI Homburg). Eur J Pediatr. 1985;144: 301-305. · DOI
  34. Merkle S, Pretsch W. Glucose-6-phosphate isomerase deficiency associated with nonspherocytic hemolytic anemia in the mouse: an animal model for the human disease. Blood. 1993;81: 206-213. · DOI
  35. Layzer RB, Rowland LP, Bank WJ. Physical and kinetic properties of human phosphofructokinase from skeletal muscle and erythrocytes. J Biol Chem. 1969;244: 3823-3831. · DOI
  36. Vora S. Isozymes of human phosphofructokinase: biochemical and genetic aspects. Isozymes Curr Top Biol Med Res. 1983;11: 3-23.
  37. Vora S, Durham S, de Martinville B, George DL, Francke U. Assignment of the human gene for muscle-type phosphofructokinase (PFKM) to chromosome 1 (region cen leads to q32) using somatic cell hybrids and monoclonal anti-M antibody. Somatic Cell Genet. 1982;8: 95-104. · DOI
  38. Yamada S, Nakajima H, Kuehn MR. Novel testis- and embryo-specific isoforms of the phosphofructokinase-1 muscle type gene. Biochem Biophys Res Commun. 2004;316: 580-587. · DOI
  39. Elson A, Levanon D, Brandeis M, et al. The structure of the human liver-type phosphofructokinase gene. Genomics. 1990;7: 47-56. · DOI
  40. Fujii H, Miwa S. Other erythrocyte enzyme deficiencies associated with non-haematological symptoms: phosphoglycerate kinase and phosphofructokinase deficiency. Baillieres Best Pract Res Clin Haematol. 2000;13: 141-148. · DOI
  41. Raben N, Sherman J, Miller F, Mena H, Plotz P. A 5′ splice junction mutation leading to exon deletion in an Ashkenazic Jewish family with phosphofructokinase deficiency (Tarui disease). J Biol Chem. 1993;268: 4963-4967. · DOI
  42. Sherman JB, Raben N, Nicastri C, et al. Common mutations in the phosphofructokinase-M gene in Ashkenazi Jewish patients with glycogenesis VII—and their population frequency. Am J Hum Genet. 1994;55: 305-313.
  43. Smith BF, Stedman H, Rajpurohit Y, et al. Molecular basis of canine muscle type phosphofructokinase deficiency. J Biol Chem. 1996;271: 20070-20074. · DOI
  44. Gamblin SJ, Davies GJ, Grimes JM, Jackson RM, Littlechild JA, Watson HC. Activity and specificity of human aldolases. J Mol Biol. 1991;219: 573-576. · DOI
  45. Izzo P, Costanzo P, Lupo A, Rippa E, Paolella G, Salvatore F. Human aldolase A gene: structural organization and tissue-specific expression by multiple promoters and alternate mRNA processing. Eur J Biochem. 1988;174: 569-578. · DOI
  46. Beutler E, Scott S, Bishop A, Margolis N, Matsumoto F, Kuhl W. Red cell aldolase deficiency and hemolytic anemia: a new syndrome. Trans Assoc Am Physicians. 1973;86: 154-166.
  47. Miwa S, Fujii H, Tani K, et al. Two cases of red cell aldolase deficiency associated with hereditary hemolytic anemia in a Japanese family. Am J Hematol. 1981;11: 425-437. · DOI
  48. Kreuder J, Borkhardt A, Repp R, et al. Brief report: inherited metabolic myopathy and hemolysis due to a mutation in aldolase A. N Engl J Med. 1996;334: 1100-1104. · DOI
  49. Yao DC, Tolan DR, Murray MF, et al. Hemolytic anemia and severe rhabdomyolysis caused by compound heterozygous mutations of the gene for erythrocyte/muscle isozyme of aldolase, ALDOA(Arg303X/Cys338Tyr). Blood. 2004;103: 2401-2403. · DOI
  50. Esposito G, Vitagliano L, Costanzo P, et al. Human aldolase A natural mutants: relationship between flexibility of the C-terminal region and enzyme function. Biochem J. 2004;380: 51-56. · DOI
  51. Kishi H, Mukai T, Hirono A, Fujii H, Miwa S, Hori K. Human aldolase A deficiency associated with a hemolytic anemia: thermolabile aldolase due to a single base mutation. Proc Natl Acad Sci U S A. 1987;84: 8623-8627. · DOI
  52. Mande SC, Mainfroid V, Kalk KH, Goraj K, Martial JA, Hol WG. Crystal structure of recombinant human triosephosphate isomerase at 2.8 Å resolution: triosephosphate isomerase-related human genetic disorders and comparison with the trypanosomal enzyme. Protein Sci. 1994;3: 810-821. · DOI
  53. Peters J, Hopkinson DA, Harris H. Genetic and non-genetic variation of triose phosphate isomerase isozymes in human tissues. Ann Hum Genet. 1973;36: 297-312. · DOI
  54. Brown JR, Daar IO, Krug JR, Maquat LE. Characterization of the functional gene and several processed pseudogenes in the human triosephosphate isomerase gene family. Mol Cell Biol. 1985;5: 1694-1706. · DOI
  55. Orosz F, Wagner G, Liliom K, et al. Enhanced association of mutant triosephosphate isomerase to red cell membranes and to brain microtubules. Proc Natl Acad Sci U S A. 2000;97: 1026-1031. · DOI
  56. Schneider AS. Triosephosphate isomerase deficiency: historical perspectives and molecular aspects. Baillieres Best Pract Res Clin Haematol. 2000;13: 119-140. · DOI
  57. Rosa R, Prehu MO, Calvin MC, Badoual J, Alix D, Girod R. Hereditary triose phosphate isomerase deficiency: seven new homozygous cases. Hum Genet. 1985;71: 235-240. · DOI
  58. Hollán S, Magócsi M, Fodor E, Horányi M, Harsányi V, Farkas T. Search for the pathogenesis of the differing phenotype in two compound heterozygote Hungarian brothers with the same genotypic triosephosphate isomerase deficiency. Proc Natl Acad Sci U S A. 1997;94: 10362-10366. · DOI
  59. Daar IO, Artymiuk PJ, Phillips DC, Maquat LE. Human triose-phosphate isomerase deficiency: a single amino acid substitution results in a thermolabile enzyme. Proc Natl Acad Sci U S A. 1986;83: 7903-7907. · DOI
  60. Orosz F, Oláh J, Alvarez M, et al. Distinct behavior of mutant triosephosphate isomerase in hemolysate and in isolated form: molecular basis of enzyme deficiency. Blood. 2001;98: 3106-3112. · DOI
  61. Schneider A, Westwood B, Yim C, et al. The 1591C mutation in triosephosphate isomerase (TPI) deficiency: tightly linked polymorphisms and a common haplotype in all known families. Blood Cells Mol Dis. 1996;22: 115-125. · DOI
  62. Zingg BC, Pretsch W, Mohrenweiser HW. Molecular analysis of four ENU induced triosephosphate isomerase null mutants in Mus musculus. Mutat Res. 1995;328: 163-173. · DOI
  63. McCarrey JR, Thomas K. Human testis-specific PGK gene lacks introns and possesses characteristics of a processed gene. Nature. 1987;326: 501-505. · DOI · Paper page
  64. Huang IY, Welch CD, Yoshida A. Complete amino acid sequence of human phosphoglycerate kinase: cyanogen bromide peptides and complete amino acid sequence. J Biol Chem. 1980;255: 6412-6420. · DOI
  65. Banks RD, Blake CC, Evans PR, et al. Sequence, structure and activity of phosphoglycerate kinase: a possible hinge-bending enzyme. Nature. 1979;279: 773-777. · DOI · Paper page
  66. Bernstein BE, Michels PA, Hol WG. Synergistic effects of substrate-induced conformational changes in phosphoglycerate kinase activation. Nature. 1997;385: 275-278. · DOI
  67. Michelson AM, Blake CC, Evans ST, Orkin SH. Structure of the human phosphoglycerate kinase gene and the intron-mediated evolution and dispersal of the nucleotide-binding domain. Proc Natl Acad Sci U S A. 1985;82: 6965-6969. · DOI
  68. Tsujino S, Shanske S, DiMauro S. Molecular genetic heterogeneity of phosphoglycerate kinase (PGK) deficiency. Muscle Nerve. 1995;3: S45-S49. · DOI
  69. Ookawara T, Dave V, Willems P, et al. Retarded and aberrant splicings caused by single exon mutation in a phosphoglycerate kinase variant. Arch Biochem Biophys. 1996;327: 35-40. · DOI
  70. Kanno H, Fujii H, Miwa S. Structural analysis of human pyruvate kinase L-gene and identification of the promoter activity in erythroid cells. Biochem Biophys Res Commun. 1992;188: 516-523. · DOI
  71. Noguchi T, Yamada K, Inoue H, Matsuda T, Tanaka T. The L- and R-type isozymes of rat pyruvate kinase are produced from a single gene by use of different promoters. J Biol Chem. 1987;262: 14366-14371. · DOI · Paper page
  72. Tani K, Fujii H, Nagata S, Miwa S. Human liver type pyruvate kinase: complete amino acid sequence and the expression in mammalian cells. Proc Natl Acad Sci U S A. 1988;85: 1792-1795. · DOI
  73. Lenzner C, Nürnberg P, Jacobasch G, Thiele B-J. Complete genomic sequence of the human PK-L/R-gene includes four intragenic polymorphisms defining different haplotype backgrounds of normal and mutant PK-genes. DNA Seq. 1997;8: 45-53. · DOI
  74. Noguchi T, Inoue H, Tanaka T. The M1- and M2- type isozymes of rat pyruvate kinase are produced from the same gene by alternative RNA splicing. J Biol Chem. 1986;261: 13807-13812. · DOI · Paper page
  75. Takegawa S, Fujii H, Miwa S. Change of pyruvate kinase isozymes from M2- to L-type during development of the red cell. Br J Haematol. 1983;54: 467-474. · DOI
  76. Max-Audit I, Testa U, Kechemir D, Titeux M, Vainchenker W, Rosa R. Pattern of pyruvate kinase isozymes in erythroleukemia cell lines and in normal human erythroblasts. Blood. 1984;64: 930-936. · DOI
  77. Max-Audit I, Kechemir D, Mitjavila MT, Vainchenker W, Rotten D, Rosa R. Pyruvate kinase synthesis and degradation by normal and pathologic cells during erythroid maturation. Blood. 1988;72: 1039-1044. · DOI
  78. Nakashima K. Further evidence of molecular alteration and aberration of erythrocyte pyruvate kinase. Clin Chim Acta. 1974;55: 245-254. · DOI
  79. Kahn A, Marie J. Pyruvate kinases from human erythrocytes and liver. Methods Enzymol. 1982;90: 131-140. · DOI
  80. Staal GEJ, Koster JF, Kamp H, van Milligen-Boersma L, Veeger C. Human erythrocyte pyruvate kinase: its purification and some properties. Biochim Biophys Acta. 1971;227: 86-96. · DOI
  81. Gupta RK, Oesterling RM. Dual divalent cation requirement for activation of pyruvate kinase; essential roles of both enzyme- and nucleotidebound metal ions. Biochemistry. 1976;15: 2881-2887. · DOI
  82. Valentini G, Chiarelli LR, Fortin R, et al. Structure and function of human erythrocyte pyruvate kinase: molecular basis of nonspherocytic hemolytic anemia. J Biol Chem. 2002;277: 23807-23814. · DOI
  83. Enriqueta Muñoz M, Ponce E. Pyruvate kinase: current status of regulatory and functional properties. Comp Biochem Physiol B Biochem Mol Biol. 2003;135: 197-218. · DOI
  84. Valentini G, Chiarelli L, Fortin R, Speranza ML, Galizzi A, Mattevi A. The allosteric regulation of pyruvate kinase. J Biol Chem. 2000;275: 18145-18152. · DOI
  85. Jurica MS, Mesecar A, Heath PJ, Shi W, Nowak T, Stoddard BL. The allosteric regulation of pyruvate kinase by fructose-1,6-bisphosphate. Structure. 1998;6: 195-210. · DOI · Paper page
  86. Wooll JO, Friesen RHE, White MA, et al. Structural and functional linkages between subunit interfaces in mammalian pyruvate kinase. J Mol Biol. 2001;312: 525-540. · DOI
  87. Beutler E, Gelbart T. Estimating the prevalence of pyruvate kinase deficiency from the gene frequency in the general white population. Blood. 2000;95: 3585-3588. · DOI
  88. Delivoria-Papadopoulos M, Oski FA, Gottlieb AJ. Oxygen-hemoglobulin dissociation curves: effect of inherited enzyme defects of the red cell. Science. 1969;165: 601-602. · DOI
  89. Ferreira P, Morais L, Costa R, et al. Hydrops fetalis associated with erythrocyte pyruvate kinase deficiency. Eur J Pediatr. 2000;159: 481-482. · DOI
  90. Kanno H, Wei DC, Chan LC, et al. Hereditary hemolytic anemia caused by diverse point mutations of pyruvate kinase gene found in Japan and Hong Kong. Blood. 1994;84: 3505-3509. · DOI
  91. Lenzner C, Nurnberg P, Jacobasch G, Gerth C, Thiele BJ. Molecular analysis of 29 pyruvate kinase-deficient patients from central Europe with hereditary hemolytic anemia. Blood. 1997;89: 1793-1799. · DOI
  92. Diez A, Gilsanz F, Martinez J, Perez-Benavente S, Meza NW, Bautista JM. Life threatening non-spherocytic haemolytic anaemia in a patient with a null mutation in the PKLR gene and no compensatory PKM gene expression. Blood. Prepublished on May 3, 2005, as DOI 10.1182/blood-2005-02-0555. · DOI
  93. Zanella A, Fermo E, Bianchi P, Valentini G. Red cell pyruvate kinase deficiency: molecular and clinical aspects. Br J Haematol. 2005;130: 11-25. · DOI
  94. van Wijk R, van Solinge WW, Nerlov C, et al. Disruption of a novel regulatory element in the erythroid-specific promoter of the human PKLR gene causes severe pyruvate kinase deficiency. Blood. 2003;101: 1596-1602. · DOI
  95. Whitney KM, Goodman SA, Bailey EM, Lothrop CD Jr. The molecular basis of canine pyruvate kinase deficiency. Exp Hematol. 1994;22: 866-874.
  96. Tsujino K, Kanno H, Hashimoto K, et al. Delayed onset of hemolytic anemia in CBA-Pk-1slc/Pk-1slc mice with a point mutation of the gene encoding red blood cell type pyruvate kinase. Blood. 1998;91: 2169-2174. · DOI
  97. Min-Oo G, Fortin A, Tam M-F, Nantel A, Stevenson MM, Gros P. Pyruvate kinase deficiency in mice protects against malaria. Nat Genet. 2003;35: 357-362. · DOI · Paper page
  98. Harkness DR. A new erythrocytic enzyme defect with hemolytic anemia: glyceraldehyde-3-phosphate dehydrogenase deficiency [abstract]. J Lab Clin Med. 1966;68: 879-880.
  99. Oski FA, Whaun J. Hemolytic anemia and red cell glyceraldehyde-3-phosphate dehydrogenase (G-3-PD) deficiency [abstract]. Clin Res. 1969;17: 427.
  100. Stefanini M. Chronic hemolytic anemia associated with erythrocyte enolase deficiency exacerbated by ingestion of nitrofurantoin. Am J Clin Pathol. 1972;58: 408-414. · DOI
  101. Boulard-Heitzmann P, Boulard M, Tallineau C, et al. Decreased red cell enolase activity in a 40-year-old woman with compensated haemolysis. Scand J Haematol. 1984;33: 401-404. · DOI
  102. Rosa R, Calvin MC, Prehu MO, Arous N. Purification of human erythrocyte phosphoglyceromutase. J Chromatogr. 1984;285: 203-209. · DOI
  103. de Atauri P, Repiso A, Oliva B, Vives-Corrons JL, Climent F, Carreras J. Characterization of the first described mutation of human red blood cell phosphoglycerate mutase. Biochim Biophys Acta. 2005;1740: 403-410. · DOI
  104. Miwa S, Nishina T, Kakehashi Y, Kitamura M, Hiratsuka A. Studies on erythrocyte metabolism in a case with hereditary deficiency of H-subunit of lactate dehydrogenase. Acta Haematol Jpn. 1971;34: 228-232.
  105. Kremer JP, Datta T, Pretsch W, Charles DJ, Dormer P. Mechanisms of compensation of hemolytic anemia in a lactate dehydrogenase mouse mutant. Exp Hematol. 1987;15: 664-670.
  106. Benesch RE, Benesch R, Yu CI. The oxygenation of hemoglobin in the presence of 2,3-diphosphoglycerate: effect of temperature, pH, ionic strength, and hemoglobin concentration. Biochemistry. 1969;8: 2567-2571. · DOI · Paper page
  107. Rosa R, Gaillardon J, Rosa J. Diphosphoglycerate mutase and 2,3-diphosphoglycerate phosphatase activities of red cells: comparative electrophoretic study. Biochem Biophys Res Commun. 1973;51: 536-542. · DOI
  108. Hass LF, Kappel WK, Miller KB, Engle RL. Evidence for structural homology between human red cell phosphoglycerate mutase and 2,3-bisphosphoglycerate synthase. J Biol Chem. 1978;253: 77-81. · DOI
  109. Wang Y, Wei Z, Bian Q, et al. Crystal structure of human bisphosphoglycerate mutase. J Biol Chem. 2004;279: 39132-39138. · DOI
  110. Joulin V, Peduzzi J, Romeo PH, et al. Molecular cloning and sequencing of the human erythrocyte 2,3-bisphosphoglycerate mutase cDNA: revised amino acid sequence. EMBO J. 1986;5: 2275-2283. · DOI
  111. Rosa R, Prehu MO, Beuzard Y, Rosa J. The first case of a complete deficiency of diphosphoglycerate mutase in human erythrocytes. J Clin Invest. 1978;62: 907-915. · DOI
  112. Lemarchandel V, Joulin V, Valentin C, et al. Compound heterozygosity in a complete erythrocyte bisphosphoglycerate mutase deficiency. Blood. 1992;80: 2643-2649. · DOI
  113. Hoyer JD, Allen SL, Beutler E, Kubik K, West C, Fairbanks VF. Erythrocytosis due to bisphosphoglycerate mutase deficiency with concurrent glucose-6-phosphate dehydrogenase (G-6-PD) deficiency. Am J Hematol. 2004;75: 205-208. · DOI

Cited by

Metadata

Authors
van Wijk, R., & van Solinge, W. W.
Venue
Blood
Publisher
American Society of Hematology
Published
2005-12-15
Volume
106
Issue
13
Pages
4034-4042
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
DOI
10.1182/blood-2005-04-1622
OpenAlex
W2141467202
Cited by
352
References
0
FWCI
2.01
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.